iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor. It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake. The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001). The chemical synthesis of iPALT has been described. Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002). 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use. iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.
See also Substituted tryptamine Propylallyltryptamine (PALT; ASR-3004)
References
External links ALiPT (iPALT) - Isomer Design